A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis
Open Access
- 1 May 2021
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 106, 71-77
Abstract
No abstract availableKeywords
All Related Versions
This publication has 9 references indexed in Scilit:
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial ResultsNew England Journal of Medicine, 2021
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2Antiviral Research, 2020
- Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation statusPharmacological Research, 2020
- Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2Nature, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020